Perkin-Elmer and PerSeptive merge
This article was originally published in Clinica
Perkin-Elmer has completed its acquisition of PerSeptive Biosystems in a transaction valued at $360 million in stock. The companies plan to combine resources to develop systems to speed up the process, and reduce the cost of, drug discovery and development.
You may also be interested in...
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Among the largest gaps in safety data is non-clinical research on CBD use's effect on developing fetus and adolescent brain, in utero/lactational exposure, reproductive toxicity and the potential for a latency period before toxicity, says FDA neuroscientist Andrew Shen.
The templates from the US agency provide guidance to manufacturers developing antibody tests for clinical or at-home use.